AI and MRI join forces to decode breast Cancer's hidden secrets
NCT ID NCT07692230
First seen Jul 09, 2026 · Last updated Jul 22, 2026 · Updated 3 times
Summary
This study combines MRI scans with detailed genetic and molecular analysis (multiomics) to improve how luminal breast cancer is classified and treated. Researchers aim to develop models that predict treatment resistance, recurrence, and spread, helping doctors choose the most effective therapy for each patient. The study involves 2,000 participants with HR+/HER2- breast cancer who have had an MRI.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a non-invasive way to classify breast cancer subtypes and predict which treatments work best for each patient.
- What could go wrong
- This is an observational study, not a treatment trial. The models may not prove accurate enough for routine clinical use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR POSITIVE/HER-2 NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan university Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.